Basic Information
| RNALocate ID: | RLID-D:11001471 |
| RNA Symbol: | hsa-miR-29b-2-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-29b-2-5p |
| RNA ID: | miRBase:MIMAT0004515 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| Tissue/Cell Line: | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
| Database: | EVmiRNA |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002585 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:11003622 | Exosome | Plasma | 23663360 |
| RLID:11003623 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000592 | Microvesicle | Fibroblasts|Mesenchymal stem cells |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-29b-2-5p | Oral squamous cell carcinoma | MNDR-E-MI-35168 |
| MNDR | hsa-miR-29b-2-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-35169 |
| MNDR | hsa-miR-29b-2-5p | Ovarian clear cell carcinoma | MNDR-E-MI-35170 |
| MNDR | hsa-miR-29b-2-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-35171 |
| MNDR | hsa-miR-29b-2-5p | Lymphoma | MNDR-E-MI-35172 |
| MNDR | hsa-miR-29b-2-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-35173 |
| MNDR | hsa-miR-29b-2-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-35174 |
| MNDR | hsa-miR-29b-2-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-35175 |
| MNDR | hsa-miR-29b-2-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-35176 |
| MNDR | hsa-miR-29b-2-5p | Her2-receptor positive breast cancer | MNDR-E-MI-35177 |
| MNDR | hsa-miR-29b-2-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-35178 |
| MNDR | hsa-miR-29b-2-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-35179 |
| MNDR | hsa-miR-29b-2-5p | Prostate cancer | MNDR-E-MI-35180 |
| MNDR | hsa-miR-29b-2-5p | Chronic lymphocytic leukemia | MNDR-E-MI-35181 |
| MNDR | hsa-miR-29b-2-5p | Alzheimer disease | MNDR-E-MI-35182 |
| MNDR | hsa-miR-29b-2-5p | Intracranial aneurysm | MNDR-E-MI-35183 |
| MNDR | hsa-miR-29b-2-5p | Esophageal carcinoma | MNDR-E-MI-35184 |
| MNDR | hsa-miR-29b-2-5p | Leukemia | MNDR-E-MI-35185 |
| MNDR | hsa-miR-29b-2-5p | Lung cancer | MNDR-E-MI-35186 |
| MNDR | hsa-miR-29b-2-5p | Parkinson disease | MNDR-E-MI-35187 |
| MNDR | hsa-miR-29b-2-5p | Breast cancer | MNDR-E-MI-35188 |
| MNDR | hsa-miR-29b-2-5p | Thyroid cancer | MNDR-E-MI-35189 |
| MNDR | hsa-miR-29b-2-5p | Pancreatic cancer | MNDR-E-MI-35190 |
| MNDR | hsa-miR-29b-2-5p | Melanoma | MNDR-E-MI-35191 |
| MNDR | hsa-miR-29b-2-5p | Rectum adenocarcinoma | MNDR-E-MI-35192 |
| MNDR | hsa-miR-29b-2-5p | Nephroblastoma | MNDR-E-MI-35193 |
| MNDR | hsa-miR-29b-2-5p | Colon cancer | MNDR-E-MI-35194 |
| MNDR | hsa-miR-29b-2-5p | Colon adenocarcinoma | MNDR-E-MI-35195 |
| MNDR | hsa-miR-29b-2-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-35196 |
| MNDR | hsa-miR-29b-2-5p | Prostate adenocarcinoma | MNDR-E-MI-35197 |
| MNDR | hsa-miR-29b-2-5p | Glioblastoma | MNDR-E-MI-35198 |
| MNDR | hsa-miR-29b-2-5p | Rhabdomyosarcoma | MNDR-E-MI-35199 |
| MNDR | hsa-miR-29b-2-5p | Osteosarcoma | MNDR-E-MI-35200 |
| MNDR | hsa-miR-29b-2-5p | Infarction middle cerebral artery | MNDR-E-MI-35201 |
| MNDR | hsa-miR-29b-2-5p | Gastric adenocarcinoma | MNDR-E-MI-35202 |
| MNDR | hsa-miR-29b-2-5p | Cervical squamous cell carcinoma | MNDR-E-MI-35203 |
| MNDR | hsa-miR-29b-2-5p | Lung squamous cell carcinoma | MNDR-E-MI-35204 |
| MNDR | hsa-miR-29b-2-5p | Lung adenocarcinoma | MNDR-E-MI-35205 |
| MNDR | hsa-miR-29b-2-5p | Ovarian carcinoma | MNDR-E-MI-35206 |
| MNDR | hsa-miR-29b-2-5p | Bladder urothelial carcinoma | MNDR-E-MI-35207 |
| MNDR | hsa-miR-29b-2-5p | Pancreatic adenocarcinoma | MNDR-E-MI-35208 |
| MNDR | hsa-miR-29b-2-5p | Carcinoma renal cell | MNDR-E-MI-35209 |
| MNDR | hsa-miR-29b-2-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-35210 |
| MNDR | hsa-miR-29b-2-5p | Renal clear cell carcinoma | MNDR-E-MI-35211 |
| MNDR | hsa-miR-29b-2-5p | Cholangiocarcinoma | MNDR-E-MI-35212 |
| MNDR | hsa-miR-29b-2-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-35213 |
| MNDR | hsa-miR-29b-2-5p | T acute lymphoblastic leukemia | MNDR-E-MI-35214 |
| MNDR | hsa-miR-29b-2-5p | Acute t cell leukemia | MNDR-E-MI-35215 |
| MNDR | hsa-miR-29b-2-5p | Adenoma | MNDR-E-MI-35216 |
| MNDR | hsa-miR-29b-2-5p | Hepatocellular carcinoma | MNDR-E-MI-35217 |
| MNDR | hsa-miR-29b-2-5p | Acute myelocytic leukemia | MNDR-E-MI-35218 |
| MNDR | hsa-miR-29b-2-5p | Colorectal cancer | MNDR-E-MI-35219 |
| MNDR | hsa-miR-29b-2-5p | Nasopharynx carcinoma | MNDR-E-MI-35220 |
| MNDR | hsa-miR-29b-2-5p | Nasopharyngeal cancer | MNDR-E-MI-35221 |
| MNDR | hsa-miR-29b-2-5p | Breast cancer her3+ negative | MNDR-E-MI-35222 |
| MNDR | hsa-miR-29b-2-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-35223 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | CASP3 | Homo sapiens | RR00278967 |
TOP